rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2011-603rsp-741Research ArticleСтатьиArticlesФЕБУКСОСТАТ - НОВЫЙ ПРЕПАРАТ В ТЕРАПИИ ПОДАГРЫFebuxostat is a novel drug in therapy for goutБарсковаВ. Г.BarskovaV Gkater1104@yahoo.com <mailto:kater1104@yahoo.com>Il'inykhE VIl'inykhE Vkater1104@yahoo.comНасоновЕвгений ЛьвовичNasonovE L-БарсковаВ. Г.BarskovaV G-IlyinykhE VIlyinykhE V-НасоновЕвгений ЛьвовичNasonovE L-201115042011492№2 (2011)5258Copyright © Барскова В.Г., Il'inykh E.V., Насонов Е.Л., Барскова В.Г., Ilyinykh E.V., Насонов Е.Л., 20112011Барскова В.Г., Il'inykh E.V., Насонов Е.Л., Барскова В.Г., Ilyinykh E.V., Насонов Е.Л.Barskova V.G., Il'inykh E.V., Nasonov E.L., Barskova V.G., Ilyinykh E.V., Nasonov E.L.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/741References<div><p>Okamoto K., Eger B.T., Nishino T. et al. An extremely potent inhibitor of xanthinoxidoreductase. J Bio Chem 2003;278(3):1848-55.</p><p>Fox I.H., Wyngaarden J.B., Kelley W.N. Depletion of erythrocyte phosphoribosylpyrophosphate in man: a newly observed effect of allopurinol. N Engl J Med 1970;283:1177- 82.</p><p>Beardmore T.D., Kelley W.N. Mechanism of allopurinol-mediated inhibition of pyrimidine biosyntesis. J Lab Clin Med 1971;78:696-704.</p><p>Nishida Y., Kamatami N., Tanimoto K., Akaoka I. Inhibition of purine nucleoside phosphorylase activity and of T-cell function with allopurinol-riboside. Agents Actions 1979;9:549-52.</p><p>Fox R.M., Royse-Smith D., O'Sallivan W.J. Orotidinuria induced by allopurinol. Science 1970;168:861-2.</p><p>Zhao L., Takano Y., Horiuchi H. Effect of febuxostat, a novel non-purine, selective inhibitor of xantine oxidase (NP-SIXO), on enzymes in purine and pyrimidine methabolism pathway. Arthr Rheum 2003;48(Suppl. 9):531.</p><p>Bruce S.P. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40:2187-94.</p><p>Grabowski B.A., Vernillet L., Khosravan R. et al. Absorbtion, metabolism and excretion of [14C] febuxostat, a novel non-purine selective inhibitor of xantine oxidase, in healthy male subject. Drug Metab Rev 2005;37:111.</p><p>Becker M.A., Kisicki J., Khosravan R. et al. Febuxostat (TMX-67), a novel non-purine selective inhibitor of xantine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004;23:1111-6.</p><p>Khosravan R., Grabowski B.A., Wu J T. et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xantine oxidase, in dose escalation study in healthy subjects. Clin Pharmacokinet 2006;45:821-41.</p><p>Komoriya K., Hoshide S., Takeda K. et al. Pharmacokinetics and pharmacodynamics and safety of febuxostat (TMX-67), a non-purine selective inhibitor of xantine oxidase/xantine dehydrogenase (NPSIXO) in patientsbwith gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2004;23:1119-22.</p><p>Mukoyoshi M., Nishimura S., Hoshide S. et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 2008;38:496-510.</p><p>Khosravan R., Kukulka M.J., Wu J.T. et al. The effect of age and gender on pharma-cokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008;48:1014-24.</p><p>Swan S., Khosravan R., Mauer M.D. et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine, selective inhibitor of xanthine oxidase. Arthr Rheum 2003;48(Suppl. 9):529.</p><p>Zhang W., Doherty M., Pascual E. et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1312-24.</p><p>Grabowski B.A., Khosravan R., Wu J.T. et al. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Arthr Rheum 2005;52:103-4. 13. 13.</p><p>Grabowski B.A., Khosravan R., Wu J.T. et al. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Br J Clin Pharmacol 2010;70(1):57-64.</p><p>Khosravan R., Mayer M.D., Wu J.T. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state. Arthr Rheum 2005;52(Suppl.)102-3.</p><p>Khosravan R., Wu J.T., Joseph-Ridge N. et al. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol 2006;46:855-66.</p><p>Khosravan R., Kukulka M.J, Wu J.T. et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008;48:1014-24.</p><p>Becker M.A., Schumacher H.R., Wortmann R.L. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthr Rheum 2005;52(3):916-23.</p><p>Seegmiller J.E. Xantine stone formation. Am J Med 1968;45:780-3.</p><p>Becker M.A., Schumacher H.R., Wortmann R.L. et al Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl J Med 2005;8:2450-61.</p><p>Schumacher H.R., Wortmann R.L., Becker M.A. et al. A phase II, long term open-label safety and efficacy study of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase. Arthr Rheum 2004;50:336.</p><p>Becker M.A., Schumacher H.R., Wortmann R. et al. Magnetic resonance imaging of gouty tophi during treatment with febuxostat, a non-purine selective inhibitor of xanthine oxidase. Arthr Rheum 2004;50:336.</p><p>Becker M.A., Schumacher H.R., Wortmann R. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients. Arthr Rheum 2004;50:336.</p><p>Schumacher H.R., Becker M.A., Wortmann R.L. et al. The FOCUS trial 48-month interim analysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension study. Ann Rheum Dis 2006;65:93.</p><p>Schumacher H.R., Becker M.A., Wortmann R.L. et al. Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study. Arthr Rheum 2005;52:680.</p><p>Wortmann R.L., Becker M.A.,</p><p>Schumacher H.R. et al. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial. ACR/ARHP Annual Scientific Meeting, 2006.</p><p>Becker M.A., Schumacher H.R., Espinoza L. et al. A phase III randomized, controlled, multicenter, double-blind trial comparing efficacy and safety of daily febuxostat and allopurinol in subjects with gout; Presented at: the Meeting of the American College of Rheumatology; October 24-29, 2008; San Francisco, California, abstr L11;57.</p><p>Sanchez-Lozada L.G., Tapia E., Bautista-Garcia P. et al. Effects of febuxostat on metabolic and renal alteration in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2008;294:710-8.</p><p>Nakagawa T., Hu H., Zharikov S. et al. A casual role of uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006;290:625-31.</p><p>EMA (European Medicines Agency) Available at: <http://www.emea.europa.eu/>humandocs/Humans/EPAR/adenuric/adenuric.htm (accessed November 10, 2008). 34.</p><p>NICE (National Institute of Health and Clinical Excellence) 2008a. Available at: <http://www.nice.org.uk/nicemedia/pdf/STA>FebuxostatGoutFAD.pdf</p></div><br /><div><p>Okamoto K., Eger B.T., Nishino T. et al. An extremely potent inhibitor of xanthinoxidoreductase. J Bio Chem 2003;278(3):1848-55.</p><p>Fox I.H., Wyngaarden J.B., Kelley W.N. Depletion of erythrocyte phosphoribosylpyrophosphate in man: a newly observed effect of allopurinol. N Engl J Med 1970;283:1177- 82.</p><p>Beardmore T.D., Kelley W.N. Mechanism of allopurinol-mediated inhibition of pyrimidine biosyntesis. J Lab Clin Med 1971;78:696-704.</p><p>Nishida Y., Kamatami N., Tanimoto K., Akaoka I. Inhibition of purine nucleoside phosphorylase activity and of T-cell function with allopurinol-riboside. Agents Actions 1979;9:549-52.</p><p>Fox R.M., Royse-Smith D., O'Sallivan W.J. Orotidinuria induced by allopurinol. Science 1970;168:861-2.</p><p>Zhao L., Takano Y., Horiuchi H. Effect of febuxostat, a novel non-purine, selective inhibitor of xantine oxidase (NP-SIXO), on enzymes in purine and pyrimidine methabolism pathway. Arthr Rheum 2003;48(Suppl. 9):531.</p><p>Bruce S.P. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40:2187-94.</p><p>Grabowski B.A., Vernillet L., Khosravan R. et al. Absorbtion, metabolism and excretion of [14C] febuxostat, a novel non-purine selective inhibitor of xantine oxidase, in healthy male subject. Drug Metab Rev 2005;37:111.</p><p>Becker M.A., Kisicki J., Khosravan R. et al. Febuxostat (TMX-67), a novel non-purine selective inhibitor of xantine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004;23:1111-6.</p><p>Khosravan R., Grabowski B.A., Wu J T. et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xantine oxidase, in dose escalation study in healthy subjects. Clin Pharmacokinet 2006;45:821-41.</p><p>Komoriya K., Hoshide S., Takeda K. et al. Pharmacokinetics and pharmacodynamics and safety of febuxostat (TMX-67), a non-purine selective inhibitor of xantine oxidase/xantine dehydrogenase (NPSIXO) in patientsbwith gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2004;23:1119-22.</p><p>Mukoyoshi M., Nishimura S., Hoshide S. et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 2008;38:496-510.</p><p>Khosravan R., Kukulka M.J., Wu J.T. et al. The effect of age and gender on pharma-cokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008;48:1014-24.</p><p>Swan S., Khosravan R., Mauer M.D. et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine, selective inhibitor of xanthine oxidase. Arthr Rheum 2003;48(Suppl. 9):529.</p><p>Zhang W., Doherty M., Pascual E. et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1312-24.</p><p>Grabowski B.A., Khosravan R., Wu J.T. et al. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Arthr Rheum 2005;52:103-4. 13. 13.</p><p>Grabowski B.A., Khosravan R., Wu J.T. et al. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Br J Clin Pharmacol 2010;70(1):57-64.</p><p>Khosravan R., Mayer M.D., Wu J.T. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state. Arthr Rheum 2005;52(Suppl.)102-3.</p><p>Khosravan R., Wu J.T., Joseph-Ridge N. et al. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol 2006;46:855-66.</p><p>Khosravan R., Kukulka M.J, Wu J.T. et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008;48:1014-24.</p><p>Becker M.A., Schumacher H.R., Wortmann R.L. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthr Rheum 2005;52(3):916-23.</p><p>Seegmiller J.E. Xantine stone formation. Am J Med 1968;45:780-3.</p><p>Becker M.A., Schumacher H.R., Wortmann R.L. et al Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl J Med 2005;8:2450-61.</p><p>Schumacher H.R., Wortmann R.L., Becker M.A. et al. A phase II, long term open-label safety and efficacy study of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase. Arthr Rheum 2004;50:336.</p><p>Becker M.A., Schumacher H.R., Wortmann R. et al. Magnetic resonance imaging of gouty tophi during treatment with febuxostat, a non-purine selective inhibitor of xanthine oxidase. Arthr Rheum 2004;50:336.</p><p>Becker M.A., Schumacher H.R., Wortmann R. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients. Arthr Rheum 2004;50:336.</p><p>Schumacher H.R., Becker M.A., Wortmann R.L. et al. The FOCUS trial 48-month interim analysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension study. Ann Rheum Dis 2006;65:93.</p><p>Schumacher H.R., Becker M.A., Wortmann R.L. et al. Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study. Arthr Rheum 2005;52:680.</p><p>Wortmann R.L., Becker M.A.,</p><p>Schumacher H.R. et al. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial. ACR/ARHP Annual Scientific Meeting, 2006.</p><p>Becker M.A., Schumacher H.R., Espinoza L. et al. A phase III randomized, controlled, multicenter, double-blind trial comparing efficacy and safety of daily febuxostat and allopurinol in subjects with gout; Presented at: the Meeting of the American College of Rheumatology; October 24-29, 2008; San Francisco, California, abstr L11;57.</p><p>Sanchez-Lozada L.G., Tapia E., Bautista-Garcia P. et al. Effects of febuxostat on metabolic and renal alteration in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2008;294:710-8.</p><p>Nakagawa T., Hu H., Zharikov S. et al. A casual role of uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006;290:625-31.</p><p>EMA (European Medicines Agency) Available at: <http://www.emea.europa.eu/>humandocs/Humans/EPAR/adenuric/adenuric.htm (accessed November 10, 2008). 34.</p><p>NICE (National Institute of Health and Clinical Excellence) 2008a. Available at: <http://www.nice.org.uk/nicemedia/pdf/STA>FebuxostatGoutFAD.pdf</p></div><br />
The authors declare that there are no conflicts of interest present.